Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma. The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma. “We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer T...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Medical News Today: Synovial sarcoma: Treatment, diagnosis, and research
What is synovial sarcoma, what are the symptoms of synovial sarcoma, and how is it diagnosed? What causes synovial sarcoma and what is the outlook? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 4, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Metastatic Synovial Sarcoma of Lung Mimicking PE and DVT Metastatic Synovial Sarcoma of Lung Mimicking PE and DVT
What can we learn from this case of metastatic synovial sarcoma initially misdiagnosed as deep venous thrombosis?Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Synovial Sarcoma man left with half a face after cancer
WARNING GRAPHIC CONTENT: Tim McGrath, 38, from Michigan, was diagnosed with Synovial Sarcoma - an extremely rare form of soft tissue cancer - leaving him with a grape fruit-sized tumour. (Source: the Mail online | Health)
Source: the Mail online | Health - July 7, 2017 Category: Consumer Health News Source Type: news

Mesothelioma Clinical Trial for Tazemetostat Launches in US
City of Hope cancer center thoracic oncologist Dr. Marianna Koczywas explains the workings of tazemetostat — the latest drug tested in a mesothelioma clinical trial — with the lock and key metaphor. “You have a specific [cancer] key, and a specific keyhole it goes through. If you can lock that keyhole, you can lock it out,” Koczywas told Asbestos.com. “These malignant cells rely on a pathway for growth and division so you try and block that specific pathway.” Koczywas is principal investigator for the mesothelioma clinical trial at the City of Hope National Medical Center in Los Angeles,...
Source: Asbestos and Mesothelioma News - August 31, 2016 Category: Environmental Health Authors: Walter Pacheco Tags: cancer treatment city of hope cancer center clinical trials at memorial sloan kettering clinical trials in california malignant pleural mesothelioma treatment marianna koczywas mesothelioma clinical trial tazemetostat Source Type: news

Adaptimmune's enhanced T-cell therapy gets FDA breakthrough status for synovial sarcoma
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for British biopharmaceutical firm Adaptimmune Therapeutics' affinity enhanced T-cell therapy targeting NY-ESO in synovial sarcoma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 10, 2016 Category: Pharmaceuticals Source Type: news

Man who married his childhood sweetheart after being diagnosed with terminal cancer sparks touching social media campaign urging people to make the most out of life
Shalin Shah, 22, from San Diego, California, was diagnosed with stage IV synovial sarcoma in August and given just months to live. He married his long-time girlfriend Frances Chen on April 24. (Source: the Mail online | Health)
Source: the Mail online | Health - May 15, 2015 Category: Consumer Health News Source Type: news

Epizyme reports positive pre-clinical results from EPZ Phase I/II trial in synovial sarcoma
US-based biopharmaceutical firm Epizyme has reported positive pre-clinical data from its Phase I/II trial of EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects you… (Source: Drug Development Technology)
Source: Drug Development Technology - October 19, 2014 Category: Pharmaceuticals Source Type: news

Synovial SarcomaSynovial Sarcoma
This brief case study reviews the diagnosis and management of synovial sarcoma, one of the most common soft-tissue tumors in young adults. Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2013 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news